ClinicalTrials.gg
WithdrawnNCT06234254Updated Sep 28, 2026

Reducing Adult Inpatients Anxiety With Virtual Reality Meditation

An interventional study of Virtual Reality headset with calming scenery in Anxiety and Virtual Reality, sponsored by Stanford University. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Stanford University · Not applicable, Interventional, and Supportive care

How we know

Why this study was withdrawn
principal investigator has no intention to start the study at this moment
Updated Sep 28, 2026Now WithdrawnStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate if non-invasive, distracting devices (virtual reality) can decrease anxiety and improve affect and satisfaction in adult, hospitalized patients.

02

Conditions studied

  • Anxiety
  • Virtual Reality

Browse trials for

03

In context

Anxiety Disorders Unverified

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

Browse Anxiety Disorders studies →

Lead sponsor

Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.

Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between age 18-99
  • hospitalized at Stanford Health Care
  • english-speaking

Exclusion criteria

Exclusion Criteria:

  • significant cognitive impairment or inability to consent
  • current nausea
  • visual problems or currently using corrective glasses that are incompatible with the virtual reality headset
  • a history of severe motion sickness
  • a history of seizures cause by flashing light
  • clinically unstable or require immediate/urgent intervention
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Virtual Reality

    Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes

    Behavioral: Virtual Reality headset with calming scenery

  • No intervention
    Control

    No intervention (i.e. virtual reality headset) will be applied to the participant.

Interventions

  • BehavioralVirtual Reality headset with calming scenery

    Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes

06

What researchers measure

Primary outcomes

  1. Hospital Anxiety and Depression Scale (HADS)

    Hospital Anxiety and Depression Scale (HADS) questionnaire. The HADS is a fourteen item scale. Seven of the items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains. Patients were defined as having anxiety or depression or both if the score was 8 or more in the corresponding subscale.

    Time frame: Before and Immediate after intervention

07

Study locations

1 site
  • Stanford Health Care (SHC)
    Palo Alto, California 94304, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Sep 2026; primary completion for May 2027, 8 months later.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Sep 2026, on Sep 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2024
First posted
Jan 31, 2024
StartEst.
Sep 24, 2026was Jun 2026
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn principal investigator has no intention to start the study at this moment
changed Sep 28, 2026
Start date
Jun 1, 2026→Sep 24, 2026
Sep 28, 2026
Enrollment
200 (estimated)→0 (actual)
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Not yet recruiting→Withdrawn
    Why stopped principal investigator has no intention to start the study at this moment
    Start date Jun 1, 2026→Sep 24, 2026
    Enrollment 200 (estimated)→0 (actual)
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06234254
Responsible party
Thomas Caruso (Clinical Professor, Stanford University) — Principal investigator
First posted
Jan 31, 2024
Start date
Sep 24, 2026 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Thomas Caruso
study director · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion